TrialEuropean heart journal. Cardiovascular pharmacotherapy2022

Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.

Philippe Gabriel Steg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.